Chicago, 31 July 2024

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, is pleased to announce that the results related to the development of its
turbidimetric NT-proBNP assay were presented at the Association for Diagnostics
& Laboratory Medicine (ADLM) 2024 clinical meeting, in Chicago, with a poster
titled: Development and diagnostic utility of immunoturbidimetric NT-proBNP
assay based on antibodies targeting glycosylation-free regions of NT-proBNP.

The presented results demonstrate good analytical performance of the Gentian
assay prototype and confirm the impact of glycosylation on measurement of
NT-proBNP in patient samples.

Current commercial assays mostly use antibodies that bind to the central region
of NT-proBNP, which is typically glycosylated. The glycosylation significantly
affects quantification of NT-proBNP in patient samples, as up to 80% of
NT-proBNP may be glycosylated in this region. The glycosylation restricts
antibody binding and thereby protein detection, leading to underestimation of
NT-proBNP levels.

Our results demonstrate the underestimation of NT-proBNP levels by assays based
on antibodies targeting glycosylated regions of NT-proBNP.  In contrast,
Gentian's NT-proBNP prototype assay targets glycosylation-free regions of the
protein and detects endogenous NT-proBNP regardless of its glycosylation status.
Our results confirm that inaccuracies caused by glycosylation are avoided by
analysis of NT-proBNP with Gentian NT-proBNP assay.

An instrument variation study showed strong correlation between values measured
on instruments from different manufacturers. These results confirm the value of
the Gentian prototype as easily accessible and available on different instrument
platforms, improving availability of the assay as well as cost and workflow
efficiency.

Please find the poster attached to this press release. 

About Gentian Diagnostics 
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Gentian's expertise and focus lies within homogenous
immunoassays, specifically infections, inflammations, kidney failures and
congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian is
headquartered in Moss, Norway, serving the global human and veterinary
diagnostics markets through sales and representative offices in Sweden, USA, and
China. For more information, please visit www.gentian.com.

IR contact:
Njaal Kind, CEO
njaal.kind@gentian.no
+47 919 06 525 (mobile)